Drug Classes and Their Effects on Behavior

Core Idea

Psychoactive drugs are categorized by their primary behavioral effects and mechanisms. Stimulants (cocaine, amphetamines) increase dopamine and norepinephrine via reuptake blockade or release, elevating arousal and mood. Depressants (alcohol, benzodiazepines) enhance GABA-A receptor function, producing sedation and anxiolysis. Opioids (morphine, heroin) activate mu-opioid receptors, reducing pain and producing euphoria via disinhibition of mesolimbic dopamine neurons. Hallucinogens (LSD, psilocybin) act primarily as serotonin 5-HT2A agonists in the cortex, disrupting sensory gating. Cannabis activates endogenous cannabinoid receptors (CB1/CB2) involved in synaptic modulation and appetite.

How It's Best Learned

Organize drugs by mechanism (what receptor/transporter they target) rather than just behavioral category, since the mechanism explains cross-drug interactions and addiction potential. The mesolimbic dopamine pathway as the common reward substrate explains why drugs as chemically diverse as cocaine and heroin both produce addiction.

Common Misconceptions

• Alcohol is not simply a social lubricant; GABA enhancement produces sedation, respiratory depression, and motor incoordination that is dose-dependent and potentially lethal.
• Hallucinogens do not 'create' hallucinations by adding signals; they alter sensory gating and prediction mechanisms, causing the brain to amplify its own internal signals.

Explainer

You already know that drugs work by acting as agonists (activating receptors) or antagonists (blocking them) at specific synaptic sites, and that synaptic transmission involves neurotransmitter release, receptor binding, and reuptake. Psychoactive drug classes are best understood as systematic exploitations of these mechanisms — each class hijacks a different molecular handle to produce its characteristic behavioral effect.

Stimulants like cocaine and amphetamines target the dopamine and norepinephrine transporters responsible for reuptake. Cocaine blocks the transporter, leaving dopamine to linger in the synapse. Amphetamines go further: they reverse the transporter, actively pumping dopamine *out* of the neuron. The result in both cases is a flood of dopamine in the nucleus accumbens — the core reward node of the mesolimbic pathway — producing intense euphoria and heightened arousal. This same dopamine surge is why stimulants are powerfully addictive: repeated use downregulates receptors, requiring more drug to achieve the same effect.

Depressants work through a completely different target. Alcohol and benzodiazepines are positive allosteric modulators at the GABA-A receptor, the brain's primary inhibitory ion channel. By enhancing chloride influx, they suppress neural firing across broad circuits — producing sedation, anxiolysis, and at high doses, respiratory depression. Because GABA is ubiquitous, depressants affect virtually every brain region, which is why alcohol impairs motor coordination, working memory, and emotional regulation simultaneously. Tolerance develops through receptor downregulation, and abrupt withdrawal can be life-threatening as rebound hyperexcitability occurs.

Opioids demonstrate how disinhibition can produce excitation. Mu-opioid receptors sit on GABAergic interneurons in the ventral tegmental area. When opioids activate these receptors, they suppress the inhibitory interneurons, *releasing* dopamine neurons from tonic inhibition — a net increase in mesolimbic dopamine despite the drug being technically an agonist at an inhibitory receptor. Opioids also directly reduce pain signaling at spinal cord and brainstem levels by hyperpolarizing pain-transmitting neurons. Hallucinogens are 5-HT2A agonists in the prefrontal cortex and sensory areas; rather than adding novel signals, they disrupt the brain's predictive filtering, allowing internally-generated patterns to dominate perception. The key organizing insight tying all of this together: despite their chemical diversity, nearly all addictive drugs converge on mesolimbic dopamine as the common reward substrate — which is why addiction shares a common behavioral signature across chemically unrelated compounds.